Trials / Completed
CompletedNCT00334295
Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
An Open, Non-randomised Multicentre Phase II Study to Assess the Efficacy and Tolerability of a 250 mg Monthly Dose of i.m. Applied Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy of a monthly administration of Fulvestrant in patients with recurrent or metastatic endometrial carcinoma by assessment of the clinical tumour response after 3 injections.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fulvestrant | A monthly intramuscular application of 250 mg Fulvestrant as a 1st line endocrine therapy in patients with recurrent or metastatic endometrial carcinoma. |
Timeline
- Start date
- 2002-12-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2006-06-07
- Last updated
- 2012-07-31
- Results posted
- 2012-07-31
Locations
9 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00334295. Inclusion in this directory is not an endorsement.